Effects of plasma kallikrein deficiency on haemostasis and thrombosis in mice: Murine Ortholog of the Fletcher Trait

Summary

Plasma kallikrein is a multifunctional serine protease involved in contact activation of coagulation. Deficiency in humans is characterised by prolonged activated partial thromboplastin time (aPTT); however, the balance between thrombosis and haemostasis is not fully understood. A study of plasma kallikrein-deficient mice revealed increased aPTT, without prolonged bleeding time. Prekallikrein antisense oligonucleotide (ASO) treatment in mice suggested potential for a positive therapeutic index. The current goal was to further define the role of plasma kallikrein in coagulation. Blood pressure and heart rate were normal in plasma kallikrein-deficient mice, and mice were completely protected from occlusion (100 ± 1.3% control flow) in 3.5% FeCl₃ -induced arterial thrombosis versus heterozygotes (20 ± 11.4%) and wild-type littermates (8 ± 0%). Vessels occluded in 8/8 wild-type, 7/8 heterozygotes, and 0/8 knockouts. Anti-thrombotic protection was less pronounced in 5% FeCl₃-induced arterial injury. Integrated blood flow was 8 ± 0% control in wild-type and heterozygotes, and significantly (p<0.01) improved to 43 ± 14.2% in knockouts. The number of vessels occluded was similar in all genotypes. Thrombus weight was significantly reduced in knockouts (−47%) and heterozygotes (−23%) versus wild-type in oxidative venous thrombosis. Average tail bleeding time increased modestly in knockout mice compared to wild-type. Average renal bleeding times were similar in all genotypes. These studies confirm and extend studies with prekallikrein ASO, and demonstrate that plasma kallikrein deletion prevents occlusive thrombus formation in mice with a minimal role in provoked bleeding. Additional support for the significance of the intrinsic pathway in the coagulation cascade is provided, as well as for a potential new anti-thrombotic approach.

Keywords

Protease - animal model - gene knockout

• References

• 1 Mandle RJ, Kaplan RP. Hageman factor substrates. J Biol Chem 1977; 252: 6097-6104.
• 2 Shariat-Madar Z, Mahdi F, Schmaier AH. Recombinant prolylcarboxypeptidase activates plasma prekallikrein. Blood 2004; 103: 4554-4561.
• 3 Hooley E, McEwan PA, Emsley J. Molecular modeling of the prekallikrein structure provides insights into high-molecular-weight kininogen binding and zymogen activation. J Thromb Haemost 2007; 5: 2461-2466.
• 4 Schmaier AH. The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction. Am J Physiol 2003; 285: R1-R13.
• 5 Clermont A, Chilcote TJ, Kita T. et al. Plasma kallikrein mediates retinal vascular dysfunction and induces retinal thickening in diabetic rats. Diabetes 2011; 60: 1590-1598.
• 6 Renné T, Pozgajová M, Grüner S. et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005; 202: 271-281.
• 7 Kleinschnitz C, Stoll G, Bendszus M. et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with haemostasis. J Exp Med 2006; 203: 513-518.
• 8 Pham M, Kleinschnitz C, Helluy X. et al. Enhanced cortical reperfusion protects coagulation factor XII-deficient mice from ischemic stroke as revealed by highfield MRI. NeuroImage 2010; 49: 2907-2914.
• 9 Renne T. The procoagulant and proinflammatory plasma contact system. Semin Immunopathol 2012; 34: 31-41.
• 10 Revenko AS, Gao D, Crosby JR. et al. Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. Blood 2011; 118: 5302-5311.
• 11 Schmaier AH, Bradford H, Silver LD. et al. High molecular weight kininogen is an inhibitor of platelet calpain. J Clin Invest 1986; 77: 1565-1573.
• 12 Puri RN, Zhou FX, Bradford H. et al. Thrombin-induced platelet aggregation involves an indirect proteolytic cleavage of aggregin by calpain. Arch Biochem Biophys 1989; 271: 346-358.
• 13 Liu J, Gao B-B, Clermont AC. et al. Hyperglycemia-induced cerebral hematoma expansion is mediated by plasma kallikrein. Nature Med 2011; 17: 206-211.
• 14 Motta G, Rojkjaer R, Hasan AA. et al. High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells: a novel mechanism for contact activation. Blood 1998; 91: 516-528.
• 15 Schmaier AH. The plasma kallikrein-kinin system counterbalances the renin-angiotensin system. J Clin Invest 2002; 109: 1007-1009.
• 16 Sealey JE, Atlas SA, Laragh JH. Linking the kallikrein and renin systems via activation of inactive renin. Am J Med 1978; 65: 994-1000.
• 17 Brown NJ, Vaughan DE. Prothrombotic effects of angiotensin. Adv Int Med 2000; 45: 419-429.
• 18 Brown NJ, Nadeau JH, Vaughan DE. Selective stimulation of tissue-type plasminogen activator (tPA) in vivo by infusion of bradykinin. Thromb Haemost 1997; 77: 522-525.
• 19 Hathaway W, Belhasen LP, Hathaway HS. Evidence for a new plasma thromboplastin factor. Blood 1965; 26: 521-532.
• 20 Wynne Jones D, Russell G, Allford SL. et al. Severe prekallikrein deficiency associated with homozygosity for an Arg94Stop nonsense mutation. Br J Hematol 2004; 127: 220-223.
• 21 Oram MP, Mumford AD, Morse C. et al. Management of anticoagulation for coronary artery bypass surgery in a patient with severe prekallikrein deficiency. J Cardiothoracic Vasc Anes 2006; 20: 580-582.
• 22 Harris MG, Exner T, Richard KA. et al. Multiple cerebral thrombosis in Fletcher factor (prekallikrein) deficiency: a case report. Am J Hematol 1985; 19: 387.
• 23 Currimbhoy Z, Vinciguerra V, Palakavongs P. et al. Fletcher factor deficiency and myocardial infarction. Am J Clin Pathol 1976; 65: 970.
• 24 Wang X, Smith PL, Hsu MY. et al. Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis. J Thromb Thrombolysis 2007; 23: 41-49.
• 25 Wang X, Cheng Q, Xu L. et al. Effects of factor IX or factor XI deficiency on ferric chlorideinduced carotid artery occlusion in mice. J Thromb Haemost 2005; 3: 695-702.
• 26 Bird JE, Smith PL, Bostwick JS. et al. Bleeding response induced by anti-thrombotic doses of a phosphoinositide 3-kinase (PI3K)-β inhibitor in mice. Thromb Res 2011; 127: 560-564.
• 27 Entes K, Laduca FM, Tourbaf KD. Fletcher factor deficiency, source of variations of the activated partial thromboplastin time test. Am J Clin Path 1981; 75: 626-628.
• 28 Qian Y, Pan J, Zhou X. et al. Molecular mechanism underlines heparin-induced thrombocytopenia and thrombosis. Prog Mol Biol Transl Sci 2010; 93: 395-421.
• 29 Abdallah RT, Keum J-S, Lee M-H. et al. Plasma kallikrein promotes epidermal growth factor receptor transactivation and signaling in vascular smooth muscle through direct activation of protease-activated receptors. J Biol Chem 2010; 285: 35206-35215.
• 30 Merkulov S, Zhang WM, Komar AA. et al. Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis. Blood 2008; 111: 1274-1281.
• 31 Adams GN, Larusch GA, Stavrou E. et al. Murine prolylcarboxypeptidase depletion induces vascular dysfunction with hypertension and faster arterial thrombosis. Blood 2011; 117: 3929-3937.
• 32 White TA, Pan S, Witt TA. et al. Murine strain differences in hemostasis and thrombosis and tissue factor pathway inhibitor. Thromb Res 2010; 125: 84-89.
• 33 Tomasini-Johansson B, Mosher DF. Plasma fibronectin concentration in inbred mouse strains. Thromb Haemost 2009; 102: 1278-1280.
• 34 Wang X, Smith PL, Hsu M-Y. et al. Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice. J Thromb Haemost 2006; 4: 1982-1988.
• 35 Chan JC, Ganopolsky JG, Cornelissen I. et al. The characterization of mice with a targeted combined deficiency of protein C and factor XI. Am J Pathol 2001; 158: 469-479.
• 36 Gruber A, Hanson SR. Factor XI-dependence of surface- and tissue factor-initiated thrombus propagation in primates. Blood 2003; 102: 953-955.
• 37 Gailani D, Renne T. The intrinsic pathway of coagulation: a target for treating thromboembolic disease?. J Thromb Haemost 2007; 5: 1106-1112.
• 38 Schumacher WA, Luettgen JM, Quan ML. et al. Inhibition of factor XIa as a new approach to anticoagulation. Arterioscler Thromb Vasc Biol 2010; 30: 388-392.
• 39 Lowenberg EC, Meijers JCM, Monia BP. et al. Coagulation factor XI as a novel target for antithrombotic treatment. J Thromb Haemost 2010; 8: 2349-2357.
• 40 Zhang H, Löwenberg EC, Crosby JR. et al. Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood 2010; 116: 4684-4692.
• 41 Cheng Q, Tucker EI, Pine MS. et al. A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood 2010; 116: 695-702.